ARCA biopharma has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) under the Coronavirus Treatment Acceleration Program (CTAP) to evaluate AB201 for the treatment of patients hospitalized with ...
Emergex Vaccines Holding, a biotechnology company developing CD8+ priming set-point vaccines to prevent serious infectious diseases, announced that it has entered into an agreement with the George Mason University, based in Virginia, in the United States.